News articles about Emergent Biosolutions (NYSE:EBS) have trended somewhat positive this week, Accern reports. The research group rates the sentiment of news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Emergent Biosolutions earned a daily sentiment score of 0.20 on Accern’s scale. Accern also gave media coverage about the biopharmaceutical company an impact score of 45.700012329862 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
These are some of the headlines that may have effected Accern Sentiment’s scoring:
- Emergent BioSolutions Inc. (EBS) has a value of $35.49 per share While Aviragen Therapeutics, Inc. (AVIR) is stand … – Stocks Gallery (stocksgallery.com)
- Insider Trading Activity Emergent Biosolutions, Inc. (NYSE:EBS) – Director Sold 10,776 shares of Stock (4-traders.com)
- Insider Selling: Emergent Biosolutions, Inc. (EBS) Director Sells 10,776 Shares of Stock (americanbankingnews.com)
- Emergent BioSolutions Inc (EBS) and Varonis Systems Inc (VRNS) Shares Needle Moving On Volume – Evergreen Caller (evergreencaller.com)
- Tale of the Ticker: Emergent BioSolutions Inc (EBS) Moves on Volume – Evergreen Caller (evergreencaller.com)
Shares of Emergent Biosolutions (EBS) opened at 34.82 on Friday. Emergent Biosolutions has a 12-month low of $24.47 and a 12-month high of $36.95. The stock has a market cap of $1.43 billion, a P/E ratio of 22.18 and a beta of 1.22. The company has a 50 day moving average price of $35.06 and a 200 day moving average price of $31.69.
A number of analysts have recently issued reports on EBS shares. Zacks Investment Research lowered Emergent Biosolutions from a “hold” rating to a “sell” rating in a research note on Monday, July 17th. BidaskClub raised Emergent Biosolutions from a “hold” rating to a “buy” rating in a research note on Saturday, June 24th. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $44.00.
In related news, Chairman Fuad El-Hibri sold 25,000 shares of Emergent Biosolutions stock in a transaction on Thursday, July 20th. The stock was sold at an average price of $35.50, for a total value of $887,500.00. Following the transaction, the chairman now owns 1,655,216 shares in the company, valued at $58,760,168. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Jerome M. Hauer sold 10,776 shares of the firm’s stock in a transaction dated Tuesday, August 15th. The shares were sold at an average price of $35.83, for a total value of $386,104.08. Following the completion of the transaction, the director now directly owns 29,421 shares in the company, valued at $1,054,154.43. The disclosure for this sale can be found here. Insiders sold 60,776 shares of company stock worth $2,186,104 in the last quarter. 16.50% of the stock is owned by insiders.
About Emergent Biosolutions
Emergent BioSolutions Inc is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs).
What are top analysts saying about Emergent Biosolutions Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Emergent Biosolutions Inc. and related companies.